Integrated proteomics and phosphoproteomics have revealed that targeting sterol O-acyltransferase 1 (SOAT1) to reduce cholesterol content in plasma membranes presents effective treatment options for early-stage HCC patients, which was further verified in a patient-derived tumor xenograft mouse model [58]. This evidence concerns the gene SOAT1 and hepatocellular carcinoma.